Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
Alpha Cognition Inc. (ACOG)
Company Research
Source: Business Wire
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting.The BEACON study is designed to assess the real-world impact of ZUNVEYL on cognition, neuropsychiatric symptoms, safety, and tolerability in patients with Alzheimer’s disease residing in nursing homes. By generating data in routine clinical practice, the study aims to complement findings from earlier clinical trials and provide practice-relevant evidence in a care setting with significant unmet need that will further support the Company’s commercialization efforts.“Enrollment of first patient in the BEACON study represents a significant milestone f
Show less
Read more
Impact Snapshot
Event Time:
ACOG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOG alerts
High impacting Alpha Cognition Inc. news events
Weekly update
A roundup of the hottest topics
ACOG
News
- Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study [Yahoo! Finance]Yahoo! Finance
- Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing RegimensBusiness Wire
- Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution [Yahoo! Finance]Yahoo! Finance
- Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial ExecutionBusiness Wire
- Alpha Cognition (NASDAQ:ACOG) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
ACOG
Analyst Actions
- 12/19/25 - HC Wainwright
ACOG
Sec Filings
- 2/24/26 - Form 4
- 2/23/26 - Form 8-K
- 2/20/26 - Form 3/A
- ACOG's page on the SEC website